Asymmetric dimethylarginine (ADMA) accelerates renal cell fibrosis under high glucose condition through NOX4/ROS/ERK signaling pathway

We previously reported that the circulatory level of Asymmetric dimethylarginine (ADMA), an endogenous competitive inhibitor of nitric oxide synthase, was increased in diabetic kidney disease patients. However, the mechanism and the role of ADMA in diabetic kidney injury remain unclear. Hence, our p...

Descripción completa

Detalles Bibliográficos
Autores principales: Jayachandran, Isaivani, Sundararajan, Saravanakumar, Venkatesan, Saravanakumar, Paadukaana, Sairaj, Balasubramanyam, Muthuswamy, Mohan, Viswanathan, Manickam, Nagaraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7525240/
https://www.ncbi.nlm.nih.gov/pubmed/32994511
http://dx.doi.org/10.1038/s41598-020-72943-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7525240/
https://www.ncbi.nlm.nih.gov/pubmed/32994511
http://dx.doi.org/10.1038/s41598-020-72943-2

Ejemplares similares